Previous 10 | Next 10 |
EYPT has had great products for some time now. They finally got their financing in order and the market loved it. Even after essentially doubling their share count, their price started going up again the next day. For further details see: EyePoint Pharmaceuticals: Time F...
WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of an underwritt...
EyePoint Pharmaceuticals (EYPT) has priced its public offering of 9.1M common shares at $11.00/share, for expected gross proceeds of $100.1M.Underwriters' over-allotment is an additional 1.365M shares. Net proceeds will be used for the advancement of EYP-1901 for wet AMD, for pipeline and com...
EyePoint Pharma (EYPT) announced that it intends to raise capital through an underwritten public offering, and use the net proceeds for the advancement of EYP-1901 for wet AMD and for its pipeline and commercial programs.The company did not give out further details on the offering.Cowen and G...
The first patient has been dosed in EyePoint Pharmaceuticals' (EYPT) Phase 1 trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD). The Phase 1 study will examine 13 patients. The primary endpoint is safet...
WATERTOWN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the first patient ...
EyePoint Pharmaceuticals (EYPT) is up ~11.9% in post-market after Cantor Fitzgerald initiated the coverage on the stock with an overweight rating. The street-high matching target of $22 implies ~2.2x of today’s close.“The potential peak sales opportunity for EYP-1901 i...
EyePoint Pharmaceuticals (EYPT) expects Q4 net product revenues to be between $6.2-$6.6M vs. $7.9M in 2019; FY20 revenues is seen in the range of $20.3-$20.7M vs. $16.8M in prior year.Analysts consensus estimate revenue to come in at $11.4M (+31.1% Y/Y) while FY20 revenue of $38.7M (+90....
- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration - - Anticipated Phase 1 clinical trial initiation in Q1 2021 - - Q4 2020 net product revenues are estimat...
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments. Ocumension Therapeutics inv...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...